Afuresertib

Target: Afuresertib targets AKT kinases, including AKT1, AKT2, and AKT3, as a pan-AKT inhibitor.

Mechanism of Action: Afuresertib can serve as a pan-AKT recognition ligand in PROTAC designs aimed at degrading AKT isoforms. The ligand-bearing end of the bifunctional molecule binds AKT, while the linker joins it to an E3 ligase ligand that recruits CRBN, VHL, or another experimentally selected ligase. Efficient degradation requires simultaneous AKT and E3 engagement in a ternary complex with favorable spatial geometry. This proximity can promote AKT ubiquitination, triggering proteasome-mediated depletion of the target protein rather than simple kinase inhibition. This establishes a testable protein-depletion mechanism for research assays.

• Kinase Degrader PROTAC Design: Afuresertib can be incorporated as a kinase-binding warhead in PROTAC constructs to recruit an E3 ligase and drive ubiquitin-dependent degradation of its target kinase. This enables systematic interrogation of kinase function by shifting from inhibition to catalytic protein removal, improving mechanistic clarity and resistance profiling in cellular models.

• Pathway Dissection via Degradation: Using Afuresertib-based PROTACs allows researchers to selectively degrade pathway-driving kinases and map downstream signaling dependencies. By comparing degradation potency and kinetics against occupancy or phosphorylation readouts, experiments can distinguish whether phenotypes arise from sustained protein loss or transient catalytic suppression.

• Resistance Mechanism Studies: Afuresertib-derived PROTACs can be used to evaluate how kinase degradation alters resistance mechanisms relative to small-molecule inhibition. Targeted protein removal can overcome certain resistance states driven by altered drug binding, and enables testing of compensatory network rewiring through time-resolved proteomics and functional assays.

• Selectivity and Off-Target Evaluation: Afuresertib’s kinase-binding profile supports PROTAC optimization aimed at improving selectivity through linker and E3 ligase selection. Researchers can assess degradation breadth using immunoblotting, proteome-wide profiling, and rescue experiments to confirm on-target dependence and quantify off-target degradation risks.

• Optimization of Degradation Kinetics: Afuresertib-based PROTACs are suitable for tuning degradation efficiency by varying linker length, attachment sites, and E3 ligase recruiters. Systematic optimization can generate constructs with distinct residence times and degradation half-lives, enabling experimental control over how quickly protein levels drop and how that timing impacts cellular phenotypes.

Afuresertib is an AKT kinase inhibitor that can serve as a target-binding ligand for exploratory AKT degrader design. Its chlorinated thiophene carboxamide and chiral aminoalkyl substituent provide a compact, polar scaffold suitable for linker-position evaluation. This molecule is described in detail below.

Structure: The molecule contains a 5-chloro thiophene-2-carboxamide coupled to a chiral amino-3-fluorophenyl propyl group and a chloromethylpyrazolyl substituent. The scaffold combines halogenated heteroaromatics, an amide, and a primary amine-bearing side chain.

Reactivity: For AKT degrader construction, the chiral aminoalkyl terminus is synthetically attractive for linker elaboration, but modification must retain the interactions responsible for AKT recognition and should be compared with parent-compound binding. PEG, alkyl, or mixed linkers can be coupled to CRBN or VHL ligands; because AKT binding is sensitive to conformational and allosteric effects, multiple linker lengths and attachment chemistries should be profiled experimentally.